Thu, Dec 25, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

UBP gains CH105m in profits in H1-2011, but assets still down as Swiss Franc continues ascent

Wednesday, August 03, 2011

Guy de Picciotto
Opalesque Industry Update - Swiss private bank and asset manager Union Bancaire Privée (UBP) recently publicized profits of CHF105.4m ($125.2m) for the first half of 2011 (H1-2011) – compared to CHF103.3m in H1-2010.

As of 30th June 2011, assets totalled CHF60.7bn ($72.1bn) – compared to CHF65bn ($69bn) as the end of 2010. Assets were therefore down by 6.6%. They were mainly affected, says the bank, by negative exchange-rate effects.

At the end of 2010, UBP had CHF65bn in AuM compared to CHF75bn a year before that – again, due to negative exchange-rate effects.

Indeed, the Swiss Franc has been climbing steadily since 2008. According to Bloomberg, the Swiss franc appreciated 2.9% to a record 1.08467 per euro in London yesterday, the steepest intraday gain since Oct. 24, 2008. The currency rose against all of its 16 major peers, reaching all-time highs against the euro, dollar and pound.

UBP’s balance sheet total reached CHF15.3bn, and the annualised return on shareholder equity for H1-2011 was 12.8%. Conservative risk-management has allowed the bank to maintain a strong financial base and a Tier 1 capital ratio of 23.6%.

Guy de Picciotto, UBP's CEO, said that the bank, which employs around 1,200 people in various locations, focused on implementing its strategic plan in Asia and other growth markets, and on strengthening its private and institutional management and sales teams on the European markets during H1-2011.

The asset management branch of UBP, which runs funds of hedge funds, was one of the first to demand of its underlying managers to have independent administrators and custodians at the end of 2008 – after suffering from heavy redemption request levels that were spurred by the credit crisis. But its image suffered in the last couple of years: it had been an indirect investor in Bernard Madoff’s funds and was was asked to pay late last year around $500m to settle claims by Madoff’s trustee. Also, the bank was allegedly an investor in some of the funds that were probed by the FBI last year, which was investigating an insider trading ring.


See Opalesque’s video interview of Larry Morgenthal, CEO and CIO of Alternatives at UBP Asset Management here: Source
And corresponding article: Opalesque Exclusive: UBP had to take a hard line with underlying managers not willing to comply with better practice Source
B. Gravrand


Bg

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its